Skip to main content
SpringerLink
Log in

Biologika bei Psoriasis: Nicht nur der Schweregrad zählt

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Hängt die Entscheidung für eine Psoriasis-Therapie mit Biologicals eher von objektiven Kriterien ab oder vom Leidensdruck der Patienten? Um diese Frage zu beantworten, haben schwedische Forscher den Einfluss von Arzt- und Patientenscores verglichen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Hägg D et al. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). JEADV 2015; 29: 452–6

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Elke Oberhofer

Authors
  1. Elke Oberhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oberhofer, E. Biologika bei Psoriasis: Nicht nur der Schweregrad zählt. hautnah dermatologie 31, 25 (2015). https://doi.org/10.1007/s15012-015-1831-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-015-1831-y

Search

Navigation